SCM
GOSS icon

Stonepine Capital Management’s Gossamer Bio GOSS Stock Holding History

Stonepine Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-204,770
Closed -$635K – 91
2025
Q4 		$635K Hold
204,770
– – 0.46% 45
2025
Q3 		$539K Buy
+204,770
New +$451K 0.44% 40
2023
Q4 		– Sell
-3,339,405
Closed -$2.78M – 19
2023
Q3 		$2.78M Buy
+3,339,405
New +$3.85M 0.92% 19

Other funds holding GOSS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Stonepine Capital Management's GOSS Position: Q1 2026 in Review

Stonepine Capital Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 204,770 shares — an estimated $635K sold.

Stonepine Capital Management first reported a position in GOSS in Q3 2023 and held it in 3 quarters. The position peaked at $2.78M in Q3 2023. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Stonepine Capital Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Stonepine Capital Management sold 204,770 Gossamer Bio shares in Q1 2026, an estimated $635K.
  • Stonepine Capital Management first reported a position in Gossamer Bio in Q3 2023 and held it in 3 quarters.
  • Stonepine Capital Management's Gossamer Bio position peaked at $2.78M in Q3 2023.
  • 184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.